Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Non-cash Items: 2019-2024

Historic Non-cash Items for Kymera Therapeutics (KYMR) over the last 6 years, with Dec 2024 value amounting to $6.2 million.

  • Kymera Therapeutics' Non-cash Items rose 20.14% to $7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.0 million, marking a year-over-year increase of 20.14%. This contributed to the annual value of $6.2 million for FY2024, which is 87.51% down from last year.
  • Latest data reveals that Kymera Therapeutics reported Non-cash Items of $6.2 million as of FY2024, which was down 87.51% from $49.6 million recorded in FY2023.
  • In the past 5 years, Kymera Therapeutics' Non-cash Items registered a high of $314.0 million during FY2020, and its lowest value of $1.9 million during FY2021.
  • Over the past 3 years, Kymera Therapeutics' median Non-cash Items value was $6.2 million (recorded in 2024), while the average stood at $19.8 million.
  • Its Non-cash Items has fluctuated over the past 5 years, first soared by 3,926.69% in 2020, then crashed by 99.39% in 2021.
  • Kymera Therapeutics' Non-cash Items (Yearly) stood at $314.0 million in 2020, then plummeted by 99.39% to $1.9 million in 2021, then surged by 81.78% to $3.5 million in 2022, then skyrocketed by 1,315.54% to $49.6 million in 2023, then crashed by 87.51% to $6.2 million in 2024.